Biological activity evaluation of novel monoamine oxidase inhibitory compounds targeting Parkinson disease.

Dawbaa, Sam; Evren, Asaf Evrim; Saglik, Begüm Nurpelin; Gundogdu-Karaburun, Nalan; Karaburun, Ahmet Cagri

Biological activity evaluation of novel monoamine oxidase inhibitory compounds targeting Parkinson disease.

Dawbaa, Sam; Evren, Asaf Evrim; Saglik, Begüm Nurpelin; Gundogdu-Karaburun, Nalan; Karaburun, Ahmet Cagri.

Afiliación

Dawbaa S; Anadolu University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Eskisehir, 26470, Turkey.
Evren AE; Department of Doctor of Pharmacy (PharmD), Thamar University, Faculty of Medical Sciences, Dhamar, 87246, Yemen.
Saglik BN; Anadolu University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Eskisehir, 26470, Turkey.
Gundogdu-Karaburun N; Bilecik Seyh Edebali University, Vocational School of Health Services, Pharmacy Services, Bilecik, 11000, Turkey.
Karaburun AC; Anadolu University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Eskisehir, 26470, Turkey.

Future Med Chem ; 14(22): 1663-1679, 2022 11.

Article en En | MEDLINE | ID: mdl-36317547

Asunto(s)

Monoaminooxidasa; Enfermedad de Parkinson; Humanos; Monoaminooxidasa/metabolismo; Inhibidores de la Monoaminooxidasa/farmacología; Inhibidores de la Monoaminooxidasa/química; Enfermedad de Parkinson/tratamiento farmacológico; Simulación del Acoplamiento Molecular; Espectrometría de Masas; Relación Estructura-Actividad; Estructura Molecular

Palabras clave

Parkinson disease; benzofuran; carbohydrazide; molecular docking; molecular dynamics simulation; monoamine oxidase inhibitors; oxadiazol

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Monoaminooxidasa Límite: Humans Idioma: En Revista: Future Med Chem Año: 2022 Tipo del documento: Article País de afiliación: Turquía

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google